Skip to main content
Equibles
HCAT logo

HCAT · Health Catalyst, Inc. · Metrics

Track HCAT — free

Use HCAT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research HCAT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.69 -0.05 (-2.87%) At close · Oct 23
Rebalance outlook locked
Market Cap
$127.18M
Shares
75.26M
Volume · Oct 23 167.4K Avg daily vol (3M) 596.95K

HCAT metrics

85 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.69
Market cap
$127.18M

Price action

20 metrics
Price change (1W)
-2.0%
Price change (30D)
-2.9%
Price change (3M)
-18.8%
Price change (6M)
+22.5%
Price change (YTD)
-29.3%
Price change (1Y)
-44.8%
Trailing year
Price change (5Y)
-96.7%
52-week high
$3.46
52-week low
$1.00
Change from 52-week high
-51.2%
Change from 52-week low
+69.7%
Annualized volatility
89.6%
Annualized volatility (3M)
69.6%
Beta
1.4
RSI (14D)
43.1
Price vs SMA 50
-1.7%
Price vs SMA 200
-2.5%
Avg volume (3M)
596,949
Relative volume
0.3
Average dollar volume
$1.09M

Company

3 metrics
Sector
Healthcare
Industry
Health Information Services
Shares outstanding
75.26M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.6×
reciprocal yield 164.9%
EV / EBITDA
—
EV / EBIT
—
P / sales
0.4×
reciprocal yield 229.8%
P / book
1.3
reciprocal yield 79.3%
FCF yield
—
TTM · current market cap
Buyback yield
0.0%
P / FCF
—
P / operating cash flow
4.5
reciprocal yield 22.2%
Earnings yield
-208.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
0.9×
reciprocal yield 109.7%
EV / revenue historical average (5Y)
0.9×
reciprocal yield 109.7%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-05
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
—
Operating margin
-84.4%
Trailing 12 months
Net margin
-90.6%
Gross profit (TTM)
—
Operating profit (TTM)
−$246.55M
Net income (TTM)
−$264.82M
Trailing 12 months
Diluted EPS (TTM)
$-3.69
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$4.06
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-3.42
EBITDA per diluted share (TTM)
$-2.75
Net income per diluted share (TTM)
$-3.68
Operating cash flow per diluted share (TTM)
$0.39
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.60
Stock compensation per diluted share (TTM)
$0.25
Book value per share
$3.34

Growth

11 metrics
Revenue growth YoY
-12.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$292.25M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+6.2%
Year over year · more shares
Revenue CAGR (3Y)
+4.0%
Revenue CAGR (5Y)
+10.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-262.6%
Return on assets
-73.8%
Debt / equity
1.5
Current ratio
2.7
EBITDA (TTM)
−$197.96M
Free cash flow (TTM)
—
Quick ratio
2.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$50.04M
Latest balance sheet
Cash & equivalents
$60.59M
Total assets
$358.60M
Total debt
$153.48M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$28.23M
Capital expenditures (TTM)
$1.21M
R&D (TTM)
$43.00M
SG&A (TTM)
—
Stock compensation (TTM)
$17.62M
R&D / revenue
14.7%
Stock compensation / revenue
6.0%

Ownership (13F)

9 metrics
13F filers
128
13F filer change QoQ
-5
Institutional ownership
74.8%
Conviction holders (share of 13F filers)
1.6%
Crowding (high-turnover and private-fund holders)
28.7%
Private-fund adviser ownership
26.0%
Active holders' share change QoQ
+3.8%
Holder tenure
14.1
Price vs estimated holder cost
-53.0%

Ownership (registered funds)

1 metrics
Index-fund ownership
8.0%

Short interest

3 metrics
Short interest
2.9%
Latest settlement · 5.2 days to cover
Days to cover
5.2d
Short-squeeze score
53 / 100

Insider activity

2 metrics
Net insider buying (90D)
$105,439
Insider-sentiment score
82 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1636422 CUSIP 42225T107 13F (30d) 15 filings 15 filers Visit website Investor relations